ABSI vs GENB
ABSI: Absci is an AI-native biopharmaceutical company shortening the timeline and cost of antibody discovery by integrating generative design with rapid lab validation. GENB: Generate Biomedicines is an AI-powered biotechnology company focused on creating a new generation of programmable protein therapeutics.
Side-by-side fundamentals
| Metric | ABSI | GENB | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.94 | $13.99 | |
| Market cap | $1.5B | $1.8B | |
| Net margin FY2024, SEC XBRL | -2274.1% | n/a | |
| Operating margin FY2024, SEC XBRL | -2401.6% | n/a | |
| ROE FY2025, SEC XBRL | -60.8% | n/a | |
| ROA FY2025, SEC XBRL | -53.3% | n/a | |
| Debt / equity as of 2026-09-03 | 0.00 | 0.01 | ABSI lower |
| Revenue growth (YoY) as of 2026-09-03 | -61.9% | -37.7% | GENB higher |
| Revenue CAGR (3y) SEC XBRL | -1.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.31 | 1.21 | |
| 1-year return as of 2026-10-08 close | +113.9% | n/a |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.